Literature DB >> 2921554

Role of post-operative electroneuronography in predicting facial nerve recovery after acoustic neuroma removal: a pilot study.

G R Croxson1, D A Moffat, D G Hardy, D M Baguley.   

Abstract

Complete clinical facial paralysis immediately after acoustic neuroma removal occurs in between 40 to 90 per cent of patients despite the fact that the facial nerve has been preserved anatomically. Some of these patients improve rapidly with adequate cosmetic and functional recovery. Others however, have incomplete or no return of useful function. A pilot study to assess the prognostic value of electroneuronography (ENOG) in 14 patients following acoustic neuroma removal was performed. The results suggest that post operative ENOG is of value in dividing those patients with anatomically intact facial nerves yet complete clinical paralysis post-operatively into groups: one with rapid improvement to an acceptable functional and cosmetic result and one with prolonged paralysis with incomplete or no recovery. Electroneuronography may thus be used to predict the initial recovery profile in patients with complete facial paralysis after surgery.

Entities:  

Mesh:

Year:  1989        PMID: 2921554     DOI: 10.1017/s0022215100108035

Source DB:  PubMed          Journal:  J Laryngol Otol        ISSN: 0022-2151            Impact factor:   1.469


  3 in total

1.  Predictive value of postoperative electrophysiologic testing of the facial nerve after cerebellopontine angle surgery.

Authors:  S H Selesnick; G P Digoy; Y Ptachewich; M Rubin; J D Victor
Journal:  Skull Base Surg       Date:  1998

2.  Prediction of facial nerve function after surgery for cerebellopontine angle tumors: use of a facial nerve stimulator and monitor.

Authors:  P J Kirkpatrick; G Watters; A J Strong; J R Walliker; M J Gleeson
Journal:  Skull Base Surg       Date:  1991

3.  Surgery for traumatic facial nerve paralysis: does intraoperative monitoring have a role?

Authors:  Yasmine A Ashram; Mohamed M K Badr-El-Dine
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-10-02       Impact factor: 2.503

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.